MRI scanner

Contact

Group lead
Prof Eric Aboagye
+44 (0)20 3313 3759
eric.aboagye@imperial.ac.uk

Cancer Imaging

Dr Laura Kenny describes how imaging is used in oncology, and provides an outline of molecular imaging research in cancer.

Disease areas

What we do

We are involved in the discovery, development and application of imaging methods, mainly positron emission tomography (PET), magnetic resonance imaging (MRI), and ultrasound (US) for clinical studies of cancer biology, physiology and pharmacology, as well as experimental studies of tumour models. Our aim is to develop methods that will make a significant impact on patient care in the short to medium term; and in the long term train the next generation of imaging scientists.

Why it is important

Our research aims to detect cancer and cancer phenotypes quicker and in a more sensitive way, as well as stratify patients more effectively to therapy, particularly in the context of drug development. The very rapid changes in molecular targets and pathways associated with anti-cancer treatment, evident in days rather than weeks, means that we can in the future detect response to therapy much earlier than current clinical standards of radiological shrinkage. Understanding disease biology in different tumour types will ultimately permit personalised medicine to be delivered to patients in the form of ‘theranostics’ (detect-and-treat).

How it can benefit patients

Our work helps in diagnosis, prognosis and treatment of cancer.

Summary of current research

  • Imaging of therapy response - development and application of caspase-3 and nucleoside salvage markers
  • Imaging of cell surface receptors and theranostic (detect & treat) applications - EGFR, SSTR2, HER2, CXCR4
  • Imaging cancer metabolism - fatty acid oxidation, glycogenesis, choline and nucleoside metabolism
  • Novel radiochemistry & radiotracer discovery and translational research
  • Radiomics and machine learning for cancer detection and prognosis.
  • Cancer pharmacology - choline kinase and HDAC6

Connections

Clinical trials

  • Development of novel imaging agents including first in man trials
  • Cancer drug development - experimental medicine (Phase I/II)
  • Imaging & molecular biomarker studies

PhD students

When we have funding for PhD studentships, we advertise them through central channels such as Find a PhD. Information is also available on the Surgery and Cancer study page. If no studentships are currently advertised, please get in touch with the group lead with proposed project titles to discuss further. 

Current PhD students:

  • Cen Chen
  • Caroline Haegeman
  • Ning Wang
  • Stanislav Piletsky (Joint with Alan Spivey, Chemistry)
  • Shah Islam (Joint with Medicine)
  • Camarie Welgemoed
  • Ala Amgheib
  • Jamie Beaumont
  • Zixuan Yang
  • Marc Boubnovski
  • Kristofer Lindon-Reid
  • Sumran Kukran
  • Luke Dixon

Our researchers

Our researchers

Benjamin Hunter

Holding

Benjamin Hunter
Honorary Clinical Research Fellow

Maria Serrano

Holding image

Maria Serrano
Clinical Trials Manager

Mohammed Al Sad

Holding image

Mohammed Al Sad
NCITA Imaging Repository Developer

Dr Louis Allott

holding

Dr Louis Allott
Research Scientist (Chemistry Lead)

Mr Chris Barnes

Holding

Mr Chris Barnes
Research Scientist

Martha Braga

Martha Braga

Martha Braga
Biology Post-doctoral scientist

Dr Diana Brickute

holding

Dr Diana Brickute
Research Associate

Mr Bhavesh Pratap

Mr Bhavesh Pratap

Mr Bhavesh Pratap
Clinical Trials Coordinator & Data Manager

Tim Hoogenboom

Holding image

Tim Hoogenboom
Research Sonographer

Xingfeng Li

Holding

Xingfeng Li
Research Associate

Cancer Imaging Research Group

                                                            Cancer imaging research group